Comparative Pharmacology
Head-to-head clinical analysis: AXITINIB versus AXTLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AXITINIB versus AXTLE.
AXITINIB vs AXTLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Axitinib is a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3). It blocks VEGF-mediated signaling, thereby inhibiting endothelial cell proliferation, migration, and survival, leading to reduced tumor angiogenesis and tumor growth.
AXTLE is a monoclonal antibody that binds to and inhibits the activity of a specific cytokine or receptor, thereby modulating immune response or cell signaling pathways involved in disease pathology.
5 mg orally twice daily (approximately 12 hours apart), with or without food; may increase to 7 mg twice daily or decrease to 3 mg twice daily based on tolerability.
10 mg orally once daily for 14 days, then 5 mg orally once daily for 14 days, then 2.5 mg orally once daily for 14 days; after 42 days, continue 2.5 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateAxitinib + Digoxin
"Axitinib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAxitinib + Digitoxin
"Axitinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAxitinib + Deslanoside
"Axitinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateAxitinib + Acetyldigitoxin
"Axitinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 2.5-6.1 hours; clinical context: supports twice-daily dosing due to rapid clearance
Terminal elimination half-life is approximately 4-6 hours in patients with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl < 30 mL/min).
Fecal (41% unchanged, 23% as metabolites); renal (<1% unchanged, 7% as metabolites)
Primarily renal elimination (70-80% unchanged); biliary/fecal excretion accounts for 15-20%; about 5% undergoes hepatic metabolism.
Category C
Category C
VEGF Receptor Tyrosine Kinase Inhibitor
VEGF Receptor Tyrosine Kinase Inhibitor